Editorial
Authors
Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, University of Sao Paulo, São Paulo, Brazil
Abstract
Drug combinations with the potential to interact comprise an important but rather neglected topic in clinical cancer research. While several studies have evaluated drug interactions in general medicine, and the potential risks for patient’s safety are well discussed, only few have addressed this subject in patients with cancer. Given the often large, and
frequently increasing, number of drugs that cancer patients take, drug–drug interactions (DDIs) may pose a real threat of undesired adverse events, of increased or decreased efficacy of antineoplastic agents and may ultimately impact on patients’ quality of life.
How common are they? Ann Oncol 2009;20:1907‑12.
2. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA,
Krzyzanowska MK. Potential drug interactions and duplicate
prescriptions among cancer patients. J Natl Cancer Inst
2007;99:592‑600.
3. Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential
for drug interactions in hospitalized cancer patients. Cancer
Chemother Pharmacol 2005;56:286‑90.
)